Track topics on Twitter Track topics that are important to you
(Reuters) - Acorda Therapeutics Inc said it halted enrolling patients in two late-stage safety studies of its Parkinson's disease drug following deaths, sending its shares tumbling more than 40 percent in premarket trading.
Original Article: Acorda reports deaths in Parkinson's trial, shares plungeNEXT ARTICLE
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...